drugset
drugset / Trial / NCT04239833

A Study of SH-1028 Tablets Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

NCT04239833 ↗

Phase 3 Unknown 240 enrolled Nanjing Sanhome Pharmaceutical, Co., Ltd.
RandomizedParallel-groupTriple-blindTreatment

Summary

To assess the efficacy and safety of SH-1028 tablets versus Gefitinib, a standard of care epidermal growth factor receptor tyrosine kinase inhibitor, in patients with locally advanced or Metastatic Non Small Cell Lung Cancer

Timeline

Start
2020-01-31
Primary completion
2022-01-31
Completion
2024-01-31

Drugs

EvaluationDrugModalityDoseRoute
Comparator Gefitinib Small molecule 250 mg Oral
Subject ORITINIB Small molecule 200 mg Oral

Indications

non-small cell lung carcinoma